Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Holdings Lifted by Strategic Investment Advisors MI

Strategic Investment Advisors MI increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 17.3% during the 1st quarter, Holdings Channel.com reports. The fund owned 1,005 shares of the medical research company’s stock after buying an additional 148 shares during the period. Strategic Investment Advisors MI’s holdings in Thermo Fisher Scientific were worth $500,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. International Assets Investment Management LLC grew its stake in Thermo Fisher Scientific by 18.1% during the 1st quarter. International Assets Investment Management LLC now owns 2,175 shares of the medical research company’s stock worth $1,082,000 after buying an additional 334 shares during the last quarter. Invesco LLC boosted its holdings in shares of Thermo Fisher Scientific by 2.6% during the first quarter. Invesco LLC now owns 11,156 shares of the medical research company’s stock valued at $5,551,000 after acquiring an additional 286 shares during the period. Proactive Wealth Strategies LLC grew its position in shares of Thermo Fisher Scientific by 4.4% during the first quarter. Proactive Wealth Strategies LLC now owns 786 shares of the medical research company’s stock worth $391,000 after acquiring an additional 33 shares during the last quarter. Sheets Smith Wealth Management lifted its position in Thermo Fisher Scientific by 3.7% in the 1st quarter. Sheets Smith Wealth Management now owns 3,010 shares of the medical research company’s stock valued at $1,498,000 after purchasing an additional 106 shares during the last quarter. Finally, Family Legacy Inc. grew its position in Thermo Fisher Scientific by 1.0% in the 1st quarter. Family Legacy Inc. now owns 2,690 shares of the medical research company’s stock worth $1,339,000 after purchasing an additional 26 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Citigroup cut their price target on Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. The Goldman Sachs Group set a $610.00 target price on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Wednesday, April 23rd. Robert W. Baird lowered their price target on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. UBS Group reduced their price objective on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating for the company in a report on Thursday, April 24th. Finally, Evercore ISI dropped their price target on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating on the stock in a research report on Thursday, April 24th. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $604.05.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares of the company’s stock, valued at approximately $9,960,188.31. This represents a 1.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $410.45 on Thursday. The stock has a market capitalization of $154.94 billion, a P/E ratio of 24.07, a P/E/G ratio of 2.13 and a beta of 0.78. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. The business’s fifty day moving average is $410.39 and its two-hundred day moving average is $485.33. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $5.10 by $0.05. The business had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. Thermo Fisher Scientific’s revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the business posted $5.11 earnings per share. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.42%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.